RobC. Four hundred arterial reconstruction operations all followed for more than one and a half years. Minerva Cardioangiol1960; 8: 31–6.
5.
BrophyCMReillyJMSmithGJWTilsonMD. The role of inflammation in nonspecific abdominal aortic aneurysm disease. Ann Vasc Surg1991; 5: 229–33.
6.
KochAEHainesGKRizzoRJHuman abdominal aortic aneurysms: immunophenotypic analysis suggesting an immunemediated response. Am J Pathol1990; 137: 1199–219.
7.
Schmitz-RixenTMegermanJColvinRBImmunosuppressive treatment of aortic allografts. J Vasc Surg1988; 7: 82–92.
8.
RobCGEastcottHHGOwenK. The reconstruction of arteries. Br J Surg1956; 43: 449–66.
9.
RobC. Arterial homografts. In: WesolowskiSADennisC, eds. Fundamentals of Vascular Grafting. New York: McGraw-Hill, 1962: 348–54.
10.
RobC. Extraperitoneal approach to the abdominal aorta. Surgery1963; 53: 88–9.
11.
CambriaRPBrewsterDCAbbottTransperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. J Vasc Surg1990; 11: 314–25.
12.
RobCGWilliamsJP. The diagnosis of aneurysms of the abdominal aorta. (An analysis of 100 patients). J. Cardiovasc Surg (Torino)1961; 2: 55–60.
13.
TilsonMDStanselHC. Differences in results for aneurysms vs. occlusive disease after bifurcation grafts: results of 100 elective grafts. Arch Surg1980; 115: 1173–5.
14.
VollmarJFPaesEPauschingerPHenzeEFrieschA. Aortic aneurysms as late sequelae of above-knee amputation. Lancet1989; ii: 834–5.
15.
PaesEHVollmarJFPauschingerPMutschlerWHenzeEFreischA. Late vascular damage after unilateral leg amputation. [German]Z Unfallchir Versicherungsmed Berufskr1990; 83: 227–36.
16.
TilsonMDNewmanKM. Proteolytic mechanisms in the pathogenesis of aortic aneurysms. In: YaoJSTPearceW, eds. Aneurysms: New Findings and Treatment. Norwalk, CT: Appleton & Lange, 1994: 3–9.
17.
KontusaariSTrompGKuivaniemiHRomanicAProckopDJ. A mutation in the gene for Type III procollagen (COL3A1) in a family with aortic aneurysms. J Clin Invest1990; 86: 1465–73.
18.
TrompGWuYProckopDJSequencing of cDNA from 50 unrelated patients reveals that mutations in the triple-helical domain of Type III procollagen are an infrequent cause of aortic aneurysms. J Clin Invest1993; 91: 2539–45.
19.
TilsonMDReillyJMBrophyCMWebsterELBarnettTR. Expression and sequence of the gene for tissue inhibitor of metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg1993; 18: 266–70.
20.
KainulainenKPulkkinenLSavolainenAKaitilaIPeltonenL. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med1990; 323: 935–9.
21.
DietzHCPyeritzREHallBDThe Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q-q21.3. Genomics1991; 9: 355–61.
22.
PyeritzRE. Marfan syndrome. N Engl J Med1990; 323: 987–9.
23.
SakaiLYKeeneDREngvallE. Fibrillin, a new 350-kD glycoprotein component of extracellular microfibrils. J Cell Biol1986; 103: 2499–509.
24.
GodfreyMMenasheVWeleberRGCosegregation of elastin-associated microfibrillar abnormalities with the Marfan phenotype in families. Am J Hum Genet1990; 46: 652–60.
25.
HollisterDWGodfreyMSakaiLYPyeritzRE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med1990; 323: 152–9.
26.
MagenisREMaslenCLSmithLLocalization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics1991; 11: 346–51.
27.
MaslenCLCorsonGMMaddoxBKGlanvilleRWSakaiLY. Partial sequence of a candidate gene for the Marfan syndrome. Nature1991; 352: 334–7.
28.
DietzHCCuttingGRPyeritzREMarfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature1991; 352: 337–9.
29.
SakaiLYKeeneDRGlanvilleRWBachingerHP. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem1991; 266: 14763–70.
30.
SpitzerSGKuppuswamyMNSainiRKasperCKBirktoftJJBajajSP. Factor IX (Hollywood): substitution of Pro55 by Ala in the first epidermal growth factor-like domain. Blood1990; 76: 1530–7.
31.
Selander-SunnerhagenMUllnerMPerssonETelemanOStenfloJDrakenbergT. How an epidermal growth factor (EFG)-like domain binds calcium. J Biol Chem1992; 267: 19642–9.
32.
HanfordPAMayhewMBaronMWinshipPRCampbellIDBrownleeGG. Key residues involved in calcium-binding motifs in EGH-like domains. Nature1991; 351: 164–7.
33.
MilewiczDMPyeritzRECrawfordESByersPH. Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. J Clin Invest1992; 89: 79–86.
34.
DietzHCSaraivaJMPyeritzRECuttingGRFrancomanoCA. Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cysteine residues in EGF-like domains. Human Mutation1992; 1: 366–74.
35.
DietzHCValleDFrancomanoCAKendziorRJJrPyeritzRECuttingGR. The skipping of constitutive exons in vivo induced by nonsense mutations. Science1993; 259: 680–2.
36.
DietzHCPyeritzREPuffenbergerEGMarfan phenotype variability in a family segregating a missense mutation in the epidermal growth factor-like motif of the fibrillin gene. J Clin Invest1992; 89: 1674–80.
37.
LehningerALNelsonDLCoxMM. Principles of Biochemistry. 2nd edn.Philadelphia: Worth Publishers, 1993: 170.